Pacific Ridge Capital Partners LLC Acquires New Stake in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Key Points

• Pacific Ridge Capital Partners LLC acquired a new stake in Sensus Healthcare, purchasing 114,500 shares for approximately $542,000, representing about 0.69% of the company.
• Multiple hedge funds including JPMorgan Chase & Co. and Barclays PLC have also made new stakes in Sensus Healthcare, indicating increased institutional interest with 25.30% of the stock held by institutional investors.
• Sensus Healthcare's latest earnings report revealed a loss of ($0.16) EPS, missing estimates, while the company reported revenues of $8.34 million, exceeding consensus expectations of $7.23 million.

Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 114,500 shares of the company's stock, valued at approximately $542,000. Pacific Ridge Capital Partners LLC owned approximately 0.69% of Sensus Healthcare at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc increased its position in Sensus Healthcare by 37.2% during the first quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock worth $89,000 after buying an additional 5,100 shares in the last quarter. Sachetta LLC boosted its holdings in shares of Sensus Healthcare by 4.1% during the first quarter. Sachetta LLC now owns 124,887 shares of the company's stock worth $591,000 after purchasing an additional 4,945 shares during the last quarter. Larson Financial Group LLC acquired a new stake in shares of Sensus Healthcare during the first quarter worth $26,000. Bank of New York Mellon Corp boosted its holdings in shares of Sensus Healthcare by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock worth $672,000 after purchasing an additional 5,289 shares during the last quarter. Finally, Chapin Davis Inc. boosted its holdings in shares of Sensus Healthcare by 50.0% during the first quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock worth $71,000 after purchasing an additional 5,000 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRTS has been the topic of a number of research analyst reports. Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Maxim Group reduced their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, May 19th.

Sensus Healthcare Trading Down 0.2%

Sensus Healthcare stock traded down $0.01 during mid-day trading on Friday, hitting $5.58. 144,164 shares of the company's stock were exchanged, compared to its average volume of 122,534. Sensus Healthcare, Inc. has a 1-year low of $4.01 and a 1-year high of $9.33. The stock has a 50 day moving average of $4.82 and a two-hundred day moving average of $5.06. The stock has a market cap of $91.74 million, a P/E ratio of 55.80 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 4.56% and a return on equity of 3.34%. The company had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.23 million. As a group, research analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.